Hengyu Lu

1.3k total citations
11 papers, 269 citations indexed

About

Hengyu Lu is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Hengyu Lu has authored 11 papers receiving a total of 269 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 4 papers in Pulmonary and Respiratory Medicine and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Hengyu Lu's work include Protein Tyrosine Phosphatases (3 papers), Lung Cancer Treatments and Mutations (3 papers) and Fibroblast Growth Factor Research (2 papers). Hengyu Lu is often cited by papers focused on Protein Tyrosine Phosphatases (3 papers), Lung Cancer Treatments and Mutations (3 papers) and Fibroblast Growth Factor Research (2 papers). Hengyu Lu collaborates with scholars based in United States, Austria and Switzerland. Hengyu Lu's co-authors include Kenneth L. Scott, Gordon B. Mills, Jeffrey A. Engelman, Peter S. Hammerman, Giordano Caponigro, Morvarid Mohseni, Huai‐Xiang Hao, Chen Liu, Jeffrey E. Lee and Eusebio Manchado and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Cancer Research and The American Journal of Human Genetics.

In The Last Decade

Hengyu Lu

11 papers receiving 267 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hengyu Lu United States 8 158 111 55 52 51 11 269
Albin Rudisch Austria 6 178 1.1× 151 1.4× 42 0.8× 54 1.0× 90 1.8× 7 325
Tomasz Tyszkiewicz Poland 11 180 1.1× 70 0.6× 52 0.9× 32 0.6× 99 1.9× 20 319
Mara Mazzoni Italy 10 196 1.2× 117 1.1× 59 1.1× 62 1.2× 58 1.1× 14 330
Hiroshi Nishimiya Japan 11 166 1.1× 120 1.1× 57 1.0× 40 0.8× 81 1.6× 23 313
Yusufu Maimaiti China 13 196 1.2× 99 0.9× 36 0.7× 54 1.0× 66 1.3× 26 389
Xiangshan Yang China 12 133 0.8× 76 0.7× 70 1.3× 42 0.8× 72 1.4× 21 295
Monika Kowal Poland 9 141 0.9× 53 0.5× 42 0.8× 31 0.6× 53 1.0× 15 258
Dae Cheon Jeong South Korea 11 200 1.3× 64 0.6× 109 2.0× 26 0.5× 139 2.7× 13 335
Giovanni Antico United States 9 147 0.9× 85 0.8× 40 0.7× 27 0.5× 72 1.4× 12 278
Sandra Di Gregorio Italy 10 108 0.7× 66 0.6× 35 0.6× 17 0.3× 41 0.8× 17 323

Countries citing papers authored by Hengyu Lu

Since Specialization
Citations

This map shows the geographic impact of Hengyu Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hengyu Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hengyu Lu more than expected).

Fields of papers citing papers by Hengyu Lu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hengyu Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hengyu Lu. The network helps show where Hengyu Lu may publish in the future.

Co-authorship network of co-authors of Hengyu Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Hengyu Lu. A scholar is included among the top collaborators of Hengyu Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hengyu Lu. Hengyu Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Wang, Weiguo, Bin Ni, Hong Shen, & Hengyu Lu. (2023). Meta-analysis of InterTan, PFNA and PFNA-II internal fixation for the treatment of unstable intertrochanteric fractures in elderly individuals. Acta Orthopaedica Belgica. 89(1). 51–58. 5 indexed citations
2.
3.
Hofmann, Marco H., Hengyu Lu, Daniel Gerlach, et al.. (2021). Abstract CT210: Trial in Process: Phase 1 studies of BI 1701963, a SOS1::KRAS Inhibitor, in combination with MEK inhibitors, irreversible KRASG12C inhibitors or irinotecan.. Cancer Research. 81(13_Supplement). CT210–CT210. 13 indexed citations
4.
Tsang, Yiu Huen, Yumeng Wang, Kathleen Kong, et al.. (2020). Differential expression of MAGEA6 toggles autophagy to promote pancreatic cancer progression. eLife. 9. 22 indexed citations
5.
Lu, Hengyu, Chen Liu, Hung Huynh, et al.. (2020). Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR. Oncotarget. 11(3). 265–281. 27 indexed citations
6.
Lu, Hengyu, Chen Liu, Roberto Velazquez, et al.. (2019). SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors. Molecular Cancer Therapeutics. 18(7). 1323–1334. 58 indexed citations
7.
Lu, Hengyu, Chen Liu, Roberto Velazquez, et al.. (2019). Abstract 954: SHP2 inhibition overcomes RTK-mediated pathway reactivation in KRAS mutant tumors treated with MEK inhibitors. 954–954. 1 indexed citations
8.
Lu, Hengyu, Turgut Dogruluk, Caitlin L. Grzeskowiak, et al.. (2017). Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer. Cancer Research. 77(13). 3502–3512. 30 indexed citations
9.
Yang, Lixing, Mi-Sook Lee, Hengyu Lu, et al.. (2016). Analyzing Somatic Genome Rearrangements in Human Cancers by Using Whole-Exome Sequencing. The American Journal of Human Genetics. 98(5). 843–856. 29 indexed citations
10.
Grubbs, Elizabeth G., Patrick Kwok‐Shing Ng, Naifa L. Busaidy, et al.. (2014). RET Fusion as a Novel Driver of Medullary Thyroid Carcinoma. The Journal of Clinical Endocrinology & Metabolism. 100(3). 788–793. 67 indexed citations
11.
Fishman, A., Joseph Chiu, Robert E. Girtanner, et al.. (1997). Phase I-II Study of Combined 5-Fluorouracil and Cisplatin Chemotherapy and Altered Fractionation Radiotherapy for Advanced Squamous Cell Carcinoma of the Cervix. American Journal of Clinical Oncology. 20(4). 342–347. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Albin Rudisch Breakdown of academic impact, for papers by Tomasz Tyszkiewicz Breakdown of academic impact, for papers by Mara Mazzoni Breakdown of academic impact, for papers by Hiroshi Nishimiya Breakdown of academic impact, for papers by Yusufu Maimaiti Breakdown of academic impact, for papers by Xiangshan Yang Breakdown of academic impact, for papers by Monika Kowal Breakdown of academic impact, for papers by Dae Cheon Jeong Breakdown of academic impact, for papers by Giovanni Antico Breakdown of academic impact, for papers by Sandra Di Gregorio
Rankless by CCL
2026